本帖最后由 老马 于 2012-1-13 21:20 编辑
9 ]+ D$ t& x. D5 p' V
4 p$ B* T _" p, ^3 N W爱必妥和阿瓦斯丁的比较
6 R* r3 w& d; ]3 |/ c( z1 E
h' `* C! ^% F9 G9 I# yhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
3 ^: y+ h% d" J; L& V O
# m! w# I K$ t( s
, k9 Y+ {7 T' e, T! Nhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, _: K6 i% \$ @" n! x$ C==================================================
7 v% E" c( a# V7 ~( F7 {) Z' VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
8 N+ U Q$ P( i: G. ?/ y8 @" T& D; NPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.7 I6 }3 s, ~) B; _
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.; w8 @+ i' }; @! S
|
显身卡
}9 Y1 n6 q. j5 j) o7 y0 V. n
